Navigation Links
Savient Announces the Election of Robert G. Savage to its Board of Directors

BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors, effective December 5, 2012.

"Bob is a proven leader with an exceptional track record of success, and we are fortunate to have a pharmaceutical executive with such a wealth of experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors.

Mr. Savage is currently President and CEO of Strategic Imagery LLC, a consulting company of which he is the principal.  Previously, Mr. Savage was Group Vice President and President of the Worldwide General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  Prior to that role, he held several senior positions with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals Group, Company Group Chairman for the North American pharmaceuticals business, President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and Marketing. Earlier in his career, he served in a variety of senior marketing, operations, business development and strategic planning positions for Hoffmann-La Roche, Inc.  Mr. Savage currently serves as a director of EpiCept Corporation, Nuovo Biologics and The Medicines Company.  Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.

"Given Bob's extensive experience in domestic and international marketing, business development and operations, we are confident that he will immediately prove to be an invaluable addition to the board and as an advisor to our senior management team especially in light of the anticipated approval and launch of KRYSTEXXA® in the EU," said Lou Ferrari, President and Chief Executive Officer of Savient.  "His strategic vision and expertise in orchestrating major product launches with renowned success will be instrumental to Savient's ongoing commitment to providing KRYSTEXXA as a treatment option to patients suffering from refractory chronic gout (RCG) in the U.S. and around the world." 

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at

SVNT - GContact:Savient Pharmaceuticals, Inc.

Burns McClellan John P. Hamill

Caitlyn MurphySenior Vice President and Chief Financial

(212) 213-0006(732) 418-9300

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
2. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
3. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
4. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Savient Pharmaceuticals Adopts Stockholder Rights Plan
6. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
7. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):